Cardiac resynchronization therapy: implant rates, temporal trends and relationships with heart failure epidemiology

Giuseppe Boriani1, Elena Berti, Laura Maria Beatrice Belotti

  • 1aInstitute of Cardiology, University of Bologna, Azienda Ospedaliera S. Orsola-Malpighi bAgency for Health and Social Care of Emilia-Romagna, Bologna cDivision of Cardiology, Parma dDivision of Cardiology, Forli' eDivision of Cardiology, Modena fDivision of Cardiology, Ravenna gDivision of Cardiology, Ferrara hDivision of Cardiology, Baggiovara (MO) iDivision of Cardiology, Reggio Emilia jDivision of Cardiology, Maggiore Hospital, Bologna kOspedale SS Annunziata Cento, AUSL Ferrara, Cento (FE), Italy.

Insights

Cardiac resynchronization therapy (CRT) use in heart failure varies significantly in real-world practice, with low overall adoption rates and unequal access across regions. Increased CRT implants were observed, but disparities persist.

Area of Science:

  • Cardiology
  • Heart Failure Management
  • Medical Device Technology

Background:

  • Consensus guidelines exist for cardiac resynchronization therapy (CRT) indications.
  • Real-world variability in CRT implant rates and its relation to heart failure epidemiology is not well-defined.

Purpose of the Study:

  • To investigate the variability in CRT implant rates in clinical practice.
  • To assess the relationship between CRT implantation and heart failure epidemiology.

Main Methods:

  • A registry collected data on CRT device implants (CRT-D or CRT-P) in Emilia-Romagna, Italy (2006-2010).
  • Data standardization across nine provinces was performed.
  • Implant rates were analyzed in relation to prevalent heart failure cases.

Main Results:

  • CRT implants increased by 71% from 2006 to 2010.
  • CRT-D devices accounted for 84-90% of implants.
  • Significant variability in standardized implant rates was observed among provinces (highest to lowest ratio > 2).
  • Proportion of prevalent heart failure patients receiving CRT annually ranged from 0.23% to 0.30%.

Conclusions:

  • Real-world application of CRT for heart failure is heterogeneous, with significant regional disparities.
  • Access to CRT treatment needs to be more equitable.
  • Despite increased use, overall CRT adoption remains low among prevalent heart failure patients.
Abstract

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pulse rhythm01:30

Pulse rhythm

Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac muscle...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...